Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus DESONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus DESONATE.
ARAZLO vs DESONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid